Gold prices steady above $3,400/oz on rate cut bets; PCE data awaited
BEDFORD, Mass. -On Wednesday, Lantheus Holdings, Inc. (NASDAQ:LNTH) reported fourth quarter earnings and revenue that surpassed analyst expectations.
Following the results the company’s shares were up 2.44% in pre-market trading.
The radiopharmaceutical-focused company posted adjusted earnings per share of $1.59, beating the consensus estimate of $1.55. Revenue for the quarter came in at $391.1 million, topping expectations of $377.24 million and representing a 10.5% increase year-over-year.
Lantheus’ flagship product PYLARIFY generated sales of $266 million in Q4, up 15.7% compared to the same period last year. The company noted PYLARIFY exceeded $1 billion in net sales for the full year 2024, becoming the first ever blockbuster radiodiagnostic.
"2024 was a groundbreaking year for Lantheus, as our radiodiagnostic, PYLARIFY, reached blockbuster status, and we enhanced our radiopharmaceutical leadership," said CEO Brian Markison.
For the full year 2025, Lantheus forecasts revenue between $1.545 billion and $1.61 billion, compared to the $1.61 billion analyst consensus. The company expects adjusted EPS of $7.00 to $7.20, above the $6.98 Wall Street estimate.
Lantheus also announced several strategic deals aimed at diversifying its portfolio with early- to late-stage assets to drive continued growth. The positive earnings report and upbeat guidance fueled the stock’s pre-market gain.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.